Coya Therapeutics, Inc. (COYA)
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies. Among its lead candidates is COYA 101, an autologous regulatory T-cell product that has successfully completed Phase 2a clinical trials for treating Amyotrophic Lateral Sclerosis (ALS). Moving towards Investigational New Drug (IND) applications are two key candidates: COYA 301 and COYA 302. COYA 301 is a Treg-enhancing biologic aimed at treating Frontotemporal Dementia. Meanwhile, COYA 302 is a dual-action biologic combination, suitable for subcutaneous or intravenous delivery, engineered to not only boost Treg function but also to diminish harmful T effector cell activity and activated macrophages in neurodegenerative and autoimmune disorders. Additionally, Coya has earlier-stage programs, including COYA 201, an allogeneic (off-the-shelf) Treg exosome candidate in preclinical development for a range of neurodegenerative, autoimmune, and metabolic conditions. Its pipeline also features COYA 206, an antigen-directed Treg-derived exosome product, currently in the discovery phase. Established in 2020, Coya Therapeutics maintains its headquarters in Houston, Texas.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Coya Therapeutics, Inc.
No splits on record
Nothing in COYA's public trading history: no forward or reverse split has affected the share count.
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Revenue | $7.95M | $3.55M | $6M | $0 | $0 | $0 |
| YoY Growth | 123.6% | -40.8% | - | - | - | - |
| Cost of Revenue | $27K | $11.87M | $5.5M | $4.41M | $0 | $0 |
| Gross Profit | $7.92M | -$8.31M | $501K | -$4.41M | $0 | $0 |
| Gross Margin | 99.7% | -233.9% | 8.3% | - | - | - |
| Research and Development | $16.73M | $11.89M | $6.04M | $4.94M | $2.54M | $373K |
| Selling, General, and Administrative | $11.45M | $8.89M | $7.83M | $4.85M | $2.31M | $669K |
| Other | $0 | -$11.84M | -$5.47M | -$4.39M | $16K | $0 |
| Total Operating Expenses | $28.18M | $8.94M | $8.4M | $5.4M | $4.87M | $1.04M |
| Operating Income (EBIT) | -$20.27M | -$17.25M | -$7.9M | -$9.81M | -$4.87M | -$1.04M |
| Operating Margin | -255.0% | -485.4% | -131.7% | - | - | - |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $39K |
| Interest Income | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Income (Expense) | -$957K | $1.65M | $639K | -$2.43M | -$21K | -$58K |
| Income Before Tax (EBT) | -$21.22M | -$15.6M | -$7.26M | -$12.24M | -$4.89M | -$1.1M |
| Income Tax Expense | $3K | -$720K | $724K | $0 | $0 | $0 |
| Net Income | -$21.23M | -$14.88M | -$7.99M | -$12.24M | -$4.89M | -$1.1M |
| Net Income Margin | -267.1% | -418.7% | -133.1% | - | - | - |
| Supplementary Data | ||||||
| EPS | -1.27 | -0.98 | -0.79 | -1.23 | -0.74 | -0.42 |
| Diluted EPS | -1.27 | -0.98 | -0.79 | -1.23 | -0.74 | -0.42 |
| Weighted Average OS | 16.73M | 15.24M | 10.16M | 9.95M | 6.60M | 2.59M |
| EBITDA | -$21.2M | -$17.2M | -$7.33M | -$9.26M | -$4.88M | $0 |
| EBITDA Margin | -266.8% | -483.9% | -122.2% | - | - | - |
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Assets | ||||||
| Current Assets | ||||||
| Cash and Cash Equivalents | $46.82M | $38.34M | $32.63M | $5.93M | $4.34M | $8.72M |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 |
| Cash and Short-Term Investments | $46.82M | $38.34M | $32.63M | $5.93M | $4.34M | $8.72M |
| Accounts Receivable | $0 | $731K | $7.5M | $0 | $0 | $1K |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Current Assets | $49.94M | $44.31M | $41.2M | $7.18M | $4.58M | $8.75M |
| Long-Term Assets | ||||||
| Property, Plant & Equipment Net | $11K | $39K | $66K | $93K | $121K | $0 |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $0 | $0 | $0 | $1.12M | $87K | $0 |
| Total Long-Term Assets | $11K | $39K | $66K | $1.21M | $208K | $0 |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $49.95M | $44.35M | $41.26M | $8.4M | $4.79M | $8.75M |
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts Payable | $1.06M | $1.59M | $1.16M | $1.82M | $858K | $447K |
| Short-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Income Tax Payable | $0 | $0 | $724K | $0 | $0 | $0 |
| Current Unearned Revenue | $1.2M | $848K | $923K | $0 | $0 | $0 |
| Other Current Liabilities | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Current Liabilities | $5.87M | $3.82M | $5.05M | $3.82M | $1.15M | $447K |
| Long-Term Liabilities | ||||||
| Long-Term Debt | $0 | $0 | $0 | $12.97M | $0 | $0 |
| Long-Term Unearned Revenue | $1.05M | $945K | $575K | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Long-Term Liabilities | $1.05M | $945K | $575K | $12.97M | $0 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $6.92M | $4.77M | $5.63M | $16.79M | $1.15M | $447K |
| Stockholders' Equity | ||||||
| Preferred Stock | $0 | $0 | $0 | $8.79M | $8.79M | $8.79M |
| Common Stock | $2K | $2K | $1K | $259 | $259 | $259 |
| Retained Earnings | -$61.96M | -$40.74M | -$25.86M | -$17.87M | -$5.62M | -$732K |
| Comprehensive Income & Other | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Stockholders' Equity | $104.99M | $80.31M | $61.49M | $9.47M | $9.27M | $9.03M |
| Total Equity | $43.03M | $39.58M | $35.64M | -$8.39M | $3.64M | $8.3M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $49.95M | $44.35M | $41.26M | $8.4M | $4.79M | $8.75M |
| Supplementary Data | ||||||
| Total Debt | $0 | $0 | $0 | $12.97M | $0 | $0 |
| Net Debt | -$46.82M | -$38.34M | -$32.63M | $7.03M | -$4.34M | -$8.72M |
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Operating Activities | ||||||
| Net Income | -$21.23M | -$14.88M | -$7.99M | -$12.24M | -$4.89M | -$733K |
| Depreciation & Amortization | $27K | $27K | $27K | $27K | $16K | $705K |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $400K | $0 |
| Stock-Based Compensation | $4.29M | $2.66M | $872K | $207K | $233K | $0 |
| Changes in Working Capital: | ||||||
| Accounts Receivable | $0 | $7.5M | -$7.5M | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | -$527K | $477K | $299K | $845K | $665K | $105K |
| Other Working Capital | $4.41M | -$6.1M | $2.56M | -$93K | $74K | -$27K |
| Total Working Capital Change | $3.88M | $1.88M | -$4.64M | $752K | $739K | $78K |
| Other Non-Cash Items | $2.29M | $25K | $543K | $4.02M | -$400K | -$441K |
| Net Cash from Operating | -$10.74M | -$10.29M | -$11.19M | -$7.24M | -$3.9M | -$391K |
| Investing Activities | ||||||
| Capital Expenditures | -$1.16M | $0 | $0 | $0 | -$137K | $0 |
| Acquisitions | $0 | $0 | $0 | $0 | $0 | $0 |
| Purchases of Investments | $0 | $0 | $0 | $0 | $0 | $0 |
| Sales of Investments | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Investing Activities | $0 | -$25K | -$543K | -$525K | $0 | $0 |
| Net Cash from Investing | -$1.16M | -$25K | -$543K | -$525K | -$137K | $0 |
| Financing Activities | ||||||
| Debt Repaid | - | - | - | -$10.47M | - | - |
| Common Stock Issuance | $20.35M | $14M | $38.34M | $158 | $1K | $9.11M |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | $0 | $2.02M | $90K | -$1.11M | -$342K | $400 |
| Net Cash from Financing | $20.39M | $16.03M | $38.43M | $9.36M | -$341K | $9.11M |
| Forex Effect | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $8.48M | $5.71M | $26.69M | $1.59M | -$4.38M | $8.72M |
| Supplementary Data | ||||||
| Operating Cash Flow | -$10.74M | -$10.29M | -$11.19M | -$7.24M | -$3.9M | -$391K |
| Capital Expenditure | $0 | $0 | $0 | $0 | -$137K | $0 |
| Free Cash Flow | -$10.74M | -$10.29M | -$11.19M | -$7.24M | -$4.04M | -$391K |
| Cash at Beginning | $38.34M | $32.63M | $5.93M | $4.34M | $8.72M | $0 |
| Cash at End | $46.82M | $38.34M | $32.63M | $5.93M | $4.34M | $8.72M |